Polaryx Therapeutics, Inc. PLYX
to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Our therapeutic philosophy
is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic
diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy,
and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs. Our small molecule
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D | $6.3M | $2.8M | — |
| SG&A | $1.6M | $1.5M | — |
| Total operating expenses | $7.8M | $4.4M | — |
| Operating income | -$7.8M | -$4.4M | — |
| Pre-tax income | -$9.0M | -$30.4M | — |
| Net income | -$9.0M | -$30.4M | — |
| EPS, basic | -0.20 | -0.89 | — |
| EPS, diluted | -0.20 | -0.89 | — |
| Shares, diluted (wtd. avg.) | $45.4M | $34.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $5.1M | $4.6M | — |
| Total current assets | $5.2M | $5.0M | — |
| Total assets | $5.2M | $5.0M | — |
| Accounts payable | $470.0K | $72.0K | — |
| Total current liabilities | $605.0K | $289.0K | — |
| Total liabilities | $605.0K | $289.0K | — |
| Retained earnings | -$99.6M | -$90.7M | — |
| Total equity | $4.6M | $4.7M | $1.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$3.9M | -$2.6M | — |
| Stock-based compensation | $4.7M | $2.4M | — |
| Financing cash flow | $4.5M | $7.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-033064.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |